HEDIS MY2024 – patient eligibility and compliance by measure

This document provides information on patient eligibility for each Healthcare Effectiveness Data and Information Set (HEDIS®) measure, including exclusion information. All information is based on HEDIS measurement year (MY) 2024 Vol. 2 technical specifications.

Breast Cancer Screening (BCS)

Continuous enrollment: Oct. 1, 2022–Dec. 31, 2024 Allowable gaps: 45 days (2023–2024) Anchor date: Dec. 31, 2024 Ages: Females 52–74 Event/diagnosis: None

Required exclusions*

- Medicare patients 66 and older (as of Dec. 31, 2024) enrolled in an Institutional Special Needs Plan (I-SNP) or living long-term in an institution (Long-Term Institutionalized [LTI] flag on enrollment file*) in 2024
- Patients from all product lines 66 and older (as of Dec. 31, 2024) with advanced illness during 2023 or 2024 and frailty during 2024
- Patients receiving palliative care during 2024
- Patients in hospice or using hospice services anytime during 2024
- Patients who died anytime during 2024
- Bilateral mastectomy in 2024 (or anytime before)

* Exclusions for advanced illness and frailty and patients living long-term in an institution are excluded based on data (i.e., monthly Centers for Medicare & Medicaid Services [CMS] enrollment file or claims/encounters, but not medical records).

Controlling Blood Pressure (CBP)

Continuous enrollment: 2024 **Allowable gaps:** 45 days **Anchor date:** Dec. 31, 2024 **Ages:** 18–75 **Event/diagnosis:** Two of the following with different dates of service (DOS) on or between Jan. 1, 2023, and June 30, 2024, with a diagnosis of hypertension: outpatient visit, telephone visit and/or online assessment

Required exclusions*

- Medicare patients 66 and older (as of Dec. 31, 2024) enrolled in an I-SNP or living long-term in an institution (LTI flag on enrollment file*) in 2024
- Patients from all product lines 81 and older (as of Dec. 31, 2024) with frailty during 2024
- Patients from all product lines 66–80 (as of Dec. 31, 2024) with advanced illness during 2023 or 2024 and frailty during 2024
- Patients receiving palliative care during 2024
- Patients in hospice or using hospice services anytime during 2024
- Diagnosis of pregnancy in 2024
- Evidence of end-stage renal disease (ESRD), dialysis, nephrectomy or kidney transplant on or prior to Dec. 31, 2024
- Patients who died anytime during 2024

Care for Older Adults (COA)

Continuous enrollment: 2024 enrolled in a Special Needs Plan (SNP) **Allowable gaps:** 45 days **Anchor date:** Dec. 31, 2024 **Ages:** 66 and older **Event/diagnosis:** None

Required exclusions*

- Patients in hospice or using hospice services anytime during 2024
- Patients who died anytime during 2024

Continuous enrollment: 2023–2024 Allowable gaps: 45 days Anchor date: Dec. 31, 2024 Ages: 45–75 Event/diagnosis: None

Required exclusions*

- Medicare patients 66 and older (as of Dec. 31, 2024) enrolled in an I-SNP plan or living long-term in an institution (LTI flag on enrollment file*) in 2024
- Patients from all product lines 66 and older (as of Dec. 31, 2024) with advanced illness during 2023 or 2024 and frailty during 2024
- Patients receiving palliative care during 2024
- Patients in hospice or using hospice services anytime during 2024
- Patients who died anytime during 2024
- · Colorectal cancer or total colectomy in 2024 (or anytime before)

Glycemic Status Assessment for Patients With Diabetes (GSD)

Continuous enrollment: 2024 **Allowable gaps:** 45 days **Anchor date:** Dec. 31, 2024 **Ages:** 18–75 **Event/diagnosis:** 2023 or 2024 claim/encounter data with at least two diagnoses of diabetes on different dates of service; or pharmacy data: dispensed insulin or hypoglycemics/antihyperglycemics and at least one diagnosis of diabetes

Required exclusions*

- Medicare patients 66 and older (as of Dec. 31, 2024) enrolled in an I-SNP plan or living long-term in an institution (LTI flag on enrollment file*) in 2024
- Patients from all product lines 66 and older (as of Dec. 31, 2024) with advanced illness during 2023 or 2024 and frailty during 2024
- Patients receiving palliative care during 2024
- Patients in hospice or using hospice services anytime during 2024
- Patients who died anytime during 2024

Eye Exam for Patients With Diabetes (EED)

Continuous enrollment: 2024 **Allowable gaps:** 45 days **Anchor date:** Dec. 31, 2024 **Ages:** 18–75 **Event/diagnosis:** 2023 or 2024 claim/encounter data with at least two diagnoses of diabetes on different dates of service or pharmacy data: dispensed insulin or hypoglycemics/antihyperglycemics and at least one diagnosis of diabetes

Required exclusions*

- Medicare patients 66 and older (as of Dec. 31, 2024) enrolled in an I-SNP plan or living long-term in an institution (LTI flag on enrollment file*) in 2024
- Patients from all product lines 66 and older (as of Dec. 31, 2024) with advanced illness during 2023 or 2024 and frailty during 2024
- Patients receiving palliative care during 2024
- Patients in hospice or using hospice services anytime during 2024
- Patients who died anytime during 2024

Kidney Health Evaluation for Patients With Diabetes (KED)

Continuous enrollment: 2024 **Allowable gaps:** 45 days **Anchor date:** Dec. 31, 2024 **Ages:** 18–75 **Event/diagnosis:** 2023 or 2024 claim/encounter data with at least two diagnoses of diabetes on different dates of service; or pharmacy data: dispensed insulin or hypoglycemics/antihyperglycemics and at least one diagnosis of diabetes

Required exclusions*

- Medicare patients 66 and older (as of Dec. 31, 2024) enrolled in an I-SNP plan or living long-term in an institution (LTI flag on enrollment file*) in 2024
- Patients from all product lines 81 and older (as of Dec. 31, 2024) with frailty during 2024
- Patients from all product lines 66 and older (as of Dec. 31, 2024) with advanced illness during 2023 or 2024 and frailty during 2024
- Patients receiving palliative care during 2024
- Patients in hospice or using hospice services anytime during 2024
- Patients who died anytime during 2024
- Patients with evidence of ESRD or dialysis anytime in or prior to 2024

Osteoporosis Management in Women Who Had a Fracture (OMW)

Continuous enrollment: 12 months before the episode date through 180 days after the episode date **Allowable gaps:** 45 days (through continuous enrollment period) **Anchor date:** Episode date **Ages:** Females 67–85 **Event/diagnosis:** Earliest fracture during the intake period (July 1, 2023–June 30, 2024)

Required exclusions*

- Medicare patients 67 and older (as of Dec. 31, 2024) enrolled in an I-SNP plan or living long-term in an institution (LTI flag on enrollment file*) in 2024
- Patients from all product lines 81 and older (as of Dec. 31, 2024) with frailty during 2024
- Patients from all product lines 67 and older (as of Dec. 31, 2024) with advanced illness during 2023 or 2024 and frailty during 2024
- Patients receiving palliative care during 2024
- Patients in hospice or using hospice services anytime during 2024
- Patients who died anytime during 2024
- Bone mineral density (BMD) test in the 24 months prior to the episode date or medication to treat osteoporosis in the 12 months before the episode date

Statin Therapy for Patients With Cardiovascular Disease (SPC)

Continuous enrollment: 2023-2024 Allowable gaps: 45 days Anchor date: Dec. 31, 2024

Ages: Females 40–75, Males 21–75 **Event/diagnosis:** Diagnosis of ischemic vascular disease in 2023 and 2024 in either an inpatient or outpatient visit (criteria need not be the same across both years)

2023 events:

- Myocardial infarction (discharge from inpatient setting)
- · Coronary artery bypass graft
- Percutaneous coronary intervention
- Other revascularization procedure

Required exclusions*

- Patients from all product lines 66 and older (as of Dec. 31, 2024) with advanced illness during 2023 or 2024 and frailty during 2024
- Patients receiving palliative care during 2024
- Patients in hospice or using hospice services anytime during 2024
- Patients who died anytime during 2024

In 2023 or 2024:

- Pregnancy diagnosis
- In vitro fertilization
- · Dispensed at least one prescription of clomiphene
- ESRD or dialysis
- Cirrhosis diagnosis
- In 2024: only myalgia, myositis, myopathy or rhabdomyolysis

Transitions of Care – Medication Reconciliation Post-Discharge (TRC)

Continuous enrollment: Date of discharge through 30 days after discharge (31 total days) **Allowable gaps:** None **Anchor date:** None **Ages:** 18 and older **Event/diagnosis:** An acute or nonacute inpatient discharge on or between Jan. 1, 2024, and Dec. 1, 2024

Required exclusions*

- Patients in hospice or using hospice services anytime during 2024
- Patients who died anytime during 2024

Follow-Up After Emergency Department Visit for People With Multiple High-Risk Chronic Conditions (FMC)

Continuous enrollment: 365 days prior to the emergency department (ED) visit through seven days after the ED visit **Allowable gaps:** No more than one gap in enrollment of up to 45 days during the 365 days prior to the ED visit and no gap during the seven days following the ED visit **Anchor date:** None **Ages:** 18 and older (as of the ED visit)

Event/diagnosis:

- An ED visit on or between Jan. 1, 2024, and Dec. 24, 2024
- Patient has two or more chronic conditions prior to the ED visit identified via claim/encounter data during 2023 or 2024 from two outpatient/nonacute inpatient encounters or one acute inpatient event

Eligible chronic conditions:

- Chronic obstructive pulmonary disease (COPD) and asthma
- · Alzheimer's disease and related disorders
- Chronic kidney disease
- Depression
- Heart failure
- Acute myocardial infarction
- Atrial fibrillation
- Stroke or transient ischemic attack

Required exclusions*

- Patients in hospice or using hospice services anytime during 2024
- Patients who died anytime during 2024

Continuous enrollment

Continuous enrollment specifies the minimum amount of time that a patient must be enrolled in an organization before becoming eligible for a measure. It ensures that the organization has enough time to render services.

Allowable gaps

A gap is the time when a patient is not covered by the organization (e.g., the time between disenrollment and reenrollment). An allowable gap can occur anytime during continuous enrollment.

Anchor date

Anchor date for a measure requires a patient to be enrolled and to have a benefit on a specific date; the allowable gap must not include that date. The patient must also have the benefit on that date.

Event/diagnosis

In addition to age, this event or diagnosis triggers the patient's eligibility for the measure and must occur in the time frame noted.

Required exclusions

Eligibility criteria that exclude the patient from the denominator, based on claims, enrollment or medical record data. This criteria is mandatory and must be used, regardless of measure compliance.

Valid data error exclusions (hospice anytime in 2023 for all)

An event or condition that makes the patient no longer eligible for the measure, based on claims or enrollment data (e.g., misdiagnosis of a disease or condition).

Valid data errors are identified only for hybrid measures during medical record review.

Note: Exclusions for advanced illness and frailty and patients living long-term in an institution are excluded based on data (i.e., monthly CMS enrollment file or claims/encounters, but not medical records).

BCS – Breast Cancer Screening

BMD - Bone mineral density test

BP – Blood pressure

- CABG Coronary artery bypass graft
- **CBP** Controlling Blood Pressure
- COA Care for Older Adults
- COL Colorectal Cancer Screening
- DC Discharge
- DOS Date of service
- ECP Eye care professional
- ED Emergency department
- EED Eye Exam for Patients With Diabetes
- ESRD End-stage renal disease

FMC – Follow-Up After Emergency Department Visit for People With Multiple High-Risk Chronic Conditions

GSD – Glycemic Status Assessment for Patients With Diabetes

IESD - Index episode start date

KED – Kidney Health Evaluation for Patients With Diabetes

MCD – Medicaid

MI – Myocardial infarction

MRP - Medication Reconciliation Post-Discharge

OMW – Osteoporosis Management in Women Who Had a Fracture

- PCI Percutaneous coronary intervention
- PCP Primary care physician
- PED Patient engagement after patient discharge
- SNP Special Needs Plan

SPC – Statin Therapy for Patients With Cardiovascular Disease

TRC – Transitions of Care

Measurement criteria

Measure	Compliance	Medical record or visit type
BCS	 Documented between Oct. 1, 2022, and Dec. 31, 2024: Mammogram (any type) 	Patient-reported data acceptable: YES Outpatient: Any visit type
СВР	 Documented in 2024: The most recent BP reading on or after the date of the second diagnosis (per claim data) BP must be less than 140/90 to be considered controlled 	Patient-reported data acceptable: YES Outpatient: PCP or practitioner managing patient's BP
HBD	 Documented in 2024: Most recent hemoglobin A1c test or glucose management indicator (GMI) and result 	Patient-reported data acceptable: YES Managing provider record: Any visit type
KED	 Documented in 2024: eGFR and uACR (or a quantitative urine albumin and urine creatinine test four days or less apart if using in place of uACR) 	Patient-reported data acceptable: YES Managing provider record: Any visit type
EED	 Documented within the appropriate time frame: Screening (retinal or dilated eye exam) performed by ECP for diabetic retinal disease in 2024 (negative or positive) Negative retinal or dilated eye exam, performed by ECP, in 2023 	Patient-reported data acceptable: YES Managing provider record: Any visit type
СОА	Documented in 2024: • Medication review • Functional status assessment • Pain assessment	Patient-reported data acceptable: NO Outpatient: Any visit type Inpatient: Nonacute setting (only)
TRC (MRP and PED)	 Documented within the appropriate time frame: Medication Reconciliation Post-Discharge: Medication reconciliation conducted by a prescribing practitioner, clinical pharmacist or registered nurse on the date of discharge through 30 days after discharge (31 days total) Patient engagement within 30 days after discharge. Do not include patient engagement that occurs on the date of discharge. 	Patient-reported data acceptable: NO Outpatient: Any visit type
FMC	 Documented within the appropriate time frame: A follow-up service within seven days after the ED visit (eight total days). Include visits that occur on the same day as the ED visit. 	Patient-reported data acceptable: NO Outpatient: Any visit type

Measure	Compliance	Medical record or visit type
COL	 Documented in the appropriate time frame, any of the following: Fecal occult blood testing (FOBT) during 2024 Stool DNA (sDNA) with fecal immunochemical test (FIT) test between 2022 and 2024 Flexible sigmoidoscopy between 2020 and 2024 Computed tomography (CT) colonography between 2020 and 2024 Colonoscopy between 2015 and 2024 	Patient-reported data acceptable: YES Outpatient: Any visit type Inpatient: Any visit
OMW	 Documentation on the date of or in the six months after a fracture (fractures occurring between July 1, 2023, and June 30, 2024): Bone mineral density testing Therapy/prescription for drug to treat/prevent osteoporosis 	Patient-reported data acceptable: NO (meds), YES (BMD testing) Outpatient: Any visit type
SPC	 Documented in 2024: Proof of a dispensing event (medication fill) for high- or moderate-intensity dose statin therapy 	Patient-reported data acceptable: NO Outpatient: Any visit type

NCQA copyright notice and disclaimer

The HEDIS measure specifications were developed by and are owned by NCQA. The HEDIS measure specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measure specifications. NCQA holds a copyright in these materials and can rescind or alter these materials at any time. These materials may not be modified by anyone other than NCQA. Use of the Rules for Allowable Adjustments of HEDIS to make permitted adjustments of the materials does not constitute

a modification. Any commercial use and/or internal or external reproduction, distribution and publication must be approved by NCQA and are subject to a license at the discretion of NCQA. Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA's Measure Certification Program. Reprinted with permission by NCQA. © 2024 NCQA, all rights reserved.

Limited proprietary coding is contained in the measure specifications for convenience. NCQA disclaims all liability for use or accuracy of any third-party code values contained in the specifications.

The full text of this notice and disclaimer is available at: http://apps.humana.com/marketing/documents.asp?file=4274309



530004ALL0824-A